Nelipepimut-S Plus GM-CSF Vaccine
Semantic Scholar uses AI to extract papers important to this topic.
Purpose: In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific… Expand The development of HER2-targeted therapy has decreased recurrence rates and improved survival, transforming the natural history… Expand E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte… Expand Purpose: E75, a peptide derived from the Her2/neu protein, is the most clinically advanced vaccine approach against breast cancer… Expand 1001Background: The role of capecitabine (X) in the adjuvant treatment of BC is not established, and few long-term survival data… Expand Background: In an adjuvant phase II trial, the HER2-derived nelipepimut-S (E75) + GM-CSF vaccine (Neuvax) has been shown to… Expand BACKGROUND
E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2… Expand Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer… Expand TPS3126 Background: We completed phase I/II clinical trials with NeuVax (nelipepimut-S), a HLA-A2/A3-restricted, HER2-derived… Expand